Latest news with #CEPI
Business Standard
4 days ago
- Health
- Business Standard
Panacea Biotec announces inclusion of EmulsiPan into prestigious CEPI Adjuvant Library
Panacea Biotec announced the listing of EmulsiPan in the CEPI (Coalition for Epidemic Preparedness Innovations) Library of adjuvants to support the scientific community in advancing vaccine and biotherapeutic development. EmulsiPan has been recognized for its potential in enhancing the efficacy and dose-sparing effects. EmulsiPan is an oil-in-water emulsion adjuvant and is produced by nano-emulsification of squalene along with surfactants and buffers. Squalene is a naturally occurring biodegradable and biocompatible triterpene hydrocarbon found in many plants as well as in humans. EmulsiPan is a ready-to-use sterile emulsion, supplied in a 10 mL USP Type I glass vial for research purposes. It is designed for storage at 2-8C and maintains stability for over 2-years under recommended conditions. On the occasion, the Chairman and Managing Director, Panacea Biotec, Dr. Rajesh Jain said, It is with great pride that we announce the availability of EmulsiPan, a ready-to-use dose sparing adjuvant designed to enhance vaccine efficacy and support global public health initiatives. Such investments showcase our commitment to research and development investments that provide us the edge to not just meet ongoing challenges but also create a future-ready company that is prepared for every possibility and opportunity.
Business Upturn
4 days ago
- Health
- Business Upturn
Panacea Biotec's EmulsiPan listed in CEPI Adjuvant Library to support vaccine development
Panacea Biotec Limited has announced the inclusion of its adjuvant, EmulsiPan, in the Coalition for Epidemic Preparedness Innovations (CEPI) Library of adjuvants. This listing aims to support researchers and developers working on vaccines and biotherapeutics. EmulsiPan is an oil-in-water emulsion adjuvant created through the nano-emulsification of squalene, surfactants, and buffers. Squalene is a naturally occurring biodegradable and biocompatible triterpene hydrocarbon found in plants and humans. EmulsiPan is supplied as a ready-to-use sterile emulsion in 10 mL USP Type I glass vials, intended for research purposes. It is stable for over two years when stored between 2-8°C. The global market for adjuvants is projected to exceed $4.8 billion by 2028, driven by applications in vaccines and biological therapies, including oncology. Oil-in-water emulsion adjuvants, such as EmulsiPan, are commonly used in commercial vaccines, including influenza vaccines. EmulsiPan's availability without licensing fees provides an accessible option for vaccine developers. EmulsiPan has been used in various preclinical studies and collaborative research projects. Notably, it was applied in non-human primate challenge studies for Sarbecoronavirus vaccine candidates at the California Institute of Technology (Caltech) and in Betacoronavirus vaccine development programs in partnership with BRIC-Translational Health Science and Technology Institute (THSTI), funded by CEPI. These studies demonstrate its adaptability and effectiveness in vaccine research. Developed in 2009 and first commercialized as part of Panacea Biotec's H1N1 vaccine, PandyFlu, EmulsiPan has since become a platform adjuvant for multiple vaccine candidates. Panacea Biotec established a cGMP manufacturing facility for EmulsiPan, ensuring consistent quality and regulatory compliance. The inclusion of EmulsiPan in the CEPI Adjuvant Library confirms it has undergone scientific evaluation and meets standards necessary to support human vaccine development. This listing is expected to increase access for researchers and companies interested in using EmulsiPan for commercial or research applications. By offering a stable, ready-to-use formulation and removing licensing fees, Panacea Biotec aims to facilitate equitable access to vaccine adjuvants and contribute to global preparedness for future epidemics and pandemics. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Yahoo
23-05-2025
- Business
- Yahoo
mRNA Platform Market and Competition Outlook 2025-2030: Virtual Trials Revolutionizing mRNA Development
The mRNA platform market holds significant opportunities, driven by advancements in LNP delivery systems, codon optimization, and synthetic biology tools like CRISPR-Cas9. These innovations support vaccine development, personalized medicine, and treatment for diseases. The rise of virtual trials further facilitates global outreach in drug development. Dublin, May 23, 2025 (GLOBE NEWSWIRE) -- The "mRNA Platform Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" has been added to offering. The mRNA Platform Market was valued at USD 7.30 Billion in 2024 and is projected to reach USD 8.93 Billion by 2030, rising at a CAGR of 3.56%. In September 2023, BioNTech SE partnered with CEPI to accelerate the development of an mRNA-based Mpox vaccine, underscoring the platform's importance in preparing for emerging infectious threats. By mimicking the natural role of RNA in the body, synthetic mRNA sequences are engineered to prompt immune responses or support therapeutic protein production. These technologies are increasingly adopted due to their adaptability, speed of development, and effectiveness, particularly in public health emergencies and personalized medicine applications. Key Market Drivers: Technological Advancements Advances in lipid nanoparticle (LNP) delivery systems have enhanced the stability and cellular uptake of mRNA molecules, improving their efficacy. These innovations were instrumental in the success of COVID-19 mRNA vaccines. Modified mRNA sequences are now more stable and less immunogenic, extending vaccine shelf life and easing distribution. For example, Sanofi launched a new mRNA research facility at Griffith University in November 2023 to accelerate drug development. Techniques like codon optimization are being refined to maximize protein expression, while synthetic biology tools such as CRISPR-Cas9 allow precise mRNA sequence design for targeted therapies. The development of cost-efficient and scalable manufacturing has also improved the availability of mRNA products during global health crises. Furthermore, enhancements in cold chain logistics and stability at varied temperature ranges reduce dependency on ultra-cold storage. The integration of next-generation sequencing supports precise and rapid design of mRNA-based treatments, enabling therapeutic applications across a broad range of indications. Key Market Challenges: Vaccine Hesitancy and Misinformation A critical challenge facing the Global mRNA Platform Market is vaccine hesitancy, fueled by misinformation. Despite scientific validation, concerns around safety, efficacy, and long-term impacts have hindered vaccine uptake. Social media platforms are often sources of misinformation, influencing public perception and eroding confidence in mRNA-based vaccines. This hesitancy can reduce immunization rates, hampering efforts to achieve herd immunity and prolonging outbreaks of preventable diseases. Public mistrust also complicates health campaigns during emergencies, such as pandemics, and may extend skepticism to other public health measures. Low vaccine coverage due to hesitancy not only affects individual health outcomes but also increases pressure on healthcare systems and obstructs disease control efforts at a population level. Key Market Trends: Increase in the Number of Virtual Trials The rise of virtual trials is reshaping drug development strategies, including those related to mRNA therapies. Virtual trials use digital platforms for remote data collection, reducing dependence on physical sites and expanding access to more diverse participant populations. CROs and pharmaceutical companies are increasingly adopting technologies such as telemedicine, wearable sensors, and mobile health apps to monitor patient outcomes in real-time. This approach enhances patient engagement, accelerates trial timelines, and reduces operational costs. The decentralized model is proving particularly effective for vaccines and therapies that require global outreach, supporting rapid data acquisition and streamlined regulatory submissions. Key Players Profiled in this mRNA Platform Market Report: AstraZeneca PLC Asuragen, Inc. Catalent Pharma Solutions Arcturus Therapeutics, Inc. BioNTech AG CRISPR Therapeutics Inc. AKESOgen, Inc. baseclick GmbH Accent Therapeutics Inc. Accanis Biotech F&E GmbH & Co KG Report Scope In this report, the Global mRNA Platform Market has been segmented into the following categories: mRNA Platform Market, by Indication: Autoimmune Diseases Cancer Personalized Treatment Single Cancer Focused Infectious Diseases Rare Diseases Respiratory Diseases mRNA Platform Market, by Usability: Prophylactic Vaccines Therapeutic Drugs Therapeutic Vaccines mRNA Platform Market, by mRNA Type: Nucleoside-Modified mRNA Self-Amplifying mRNA Unmodified mRNA mRNA Platform Market, by End-User: Hospitals & Clinics Pharmaceutical Companies Research Organization mRNA Platform Market, by Region: North America Asia-Pacific Europe South America Middle East & Africa Key Attributes Report Attribute Details No. of Pages 180 Forecast Period 2024-2030 Estimated Market Value (USD) in 2024 $7.3 Billion Forecasted Market Value (USD) by 2030 $8.93 Billion Compound Annual Growth Rate 3.5% Regions Covered Global For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Time of India
17-05-2025
- Politics
- Time of India
Enemy Property
History's heavy hand How hundreds of families became trapped in a legal battle over a label they never chose One of my uncles had gone to Pakistan for work and returned in 1958. Our ancestral property was divided about 20 years ago,' explains Abdu Khader of Nannambra in Malappuram. 'Yet, I received a Central govt notice claiming my land is enemy property.' In Sept 2024, Khader and scores of others mostly in Malappuram as well as in Kannur, Kozhikode and Palakkad, received notices from the Custodian of Enemy Property for India (CEPI), stating their properties are subject to govt takeover. The notices, dated Sept 19, gave residents just 15 days to respond. Failure to reply, the notice warned, would be considered consent for the govt to seize the land. 'I've been living here with my family since 1978. I don't understand how, all of a sudden, my property has been labelled as enemy property,' says Sujatha, a resident of Thalakkad, also in Malappuram. The plot of land in question is among the 68 properties in Kerala—worth a staggering around Rs 1,375 crore—that have been designated as 'enemy property.' The Enemy Property Act came into force in 1968 after the war with Pakistan. It aimed to regulate properties of those who migrated to Pakistan after the 1947 partition or during the 1965 and 1971 conflicts and took up citizenship there or are presumed to be Pakistani nationals. But for many families like Khader's, these labels don't reflect their reality. The law has ensnared families who have lived peacefully for generations. Many of these cases trace back to ancestors who migrated temporarily—or under compulsion—decades ago, whether for work or trade. At the time, moving to Karachi was no different than travelling to Mumbai or Kolkata. Hundreds left for ordinary jobs: Running tea stalls, working in hotels or beedi factories, trading betel leaves—just as they might have moved to any other Indian city. Most never intended to stay forever. Yet, when they tried to return, they were met with visa rejections or deportation. One such family found hope in the courtroom. Kunji Koya, a Parappanangadi native, had moved to Karachi in 1953 for working in a hotel. Though he returned to India, he was branded as a Pakistani national by the police. His son, P Ummer Koya, endured a long legal battle just to pay land tax on property he bought from his father. In a landmark Kerala high court ruling in June 2024, the court clarified that seeking employment in Pakistan does not make one an 'enemy' under the law. It quashed the proceedings, affirming the family's right to their property. 'By no stretch of the imagination can the petitioner's father or the property held by him be deemed 'enemy' under the Act,' the court ruled. Yet this ruling remains the exception, not the norm. Several families remain mired in uncertainty. Their appeals to district officials and political leaders have yielded little result. In Thalakkad panchayat in Tirur, over 35 families now find themselves unable to pay land tax. Though they had regularly paid until 2024, revenue officials are now refusing payments. 'CEPI has collected details of these properties and it is verifying the claims of property holders. We don't know how long the process will take. Until then, we cannot accept tax from them,' says R Rajiv, village officer, Thalakkad. A similar situation prevails in Nannambra panchayat, where 10 families are affected. Notices were served directly by CEPI officials from Mumbai, leaving local revenue officers with no authority. 'Residents can appeal to CEPI as mentioned in the order. We have no role in it,' says N Jayasankar, village officer in Nannambra. When tensions between India and Pakistan rise, fear among affected families deepens. 'I have lived here for over three decades, paying my taxes,' says one resident, requesting anonymity. 'This notice has plunged us into despair. While I plead with authorities to show compassion, the worsening relationship between India and Pakistan gives me nightmares.' The plight of these families has been worsened by the 2017 amendment to the Enemy Property Act. It invalidates legal sales of these properties and erects formidable barriers for those seeking legal recourse, shutting the doors of civil courts to their pleas. Kerala ranks 13th in the country in the number of enemy properties, with 38 located in Malappuram district alone. Many of these properties have changed hands multiple times, with buyers unaware of their historical baggage—until the notices arrived. 'As of now, six properties have been confirmed as enemy property and will be auctioned,' said Vinil PK, an official at Malappuram district collectorate who deals with enemy property. 'The rest are still under verification,' he said. 'Our political parties, MLAs, and MPs should take up the issue with the Centre and convince it of the plight of these hapless people,' says former MLA and film director PT Kunhi Mohammed who wrote and directed 'Paradeshi,' which depicts the plight of 'Pak citizens' in Kerala. 'Many had to take Pakistani passports to return to India but were denied Indian citizenship and lived in fear of deportation. Now their descendants face losing their hard-earned properties.' Every time the India-Pakistan situation flares up, these families are gripped by fear, uncertain of when the next blow might fall. Facebook Twitter Linkedin Email Disclaimer Views expressed above are the author's own.
Yahoo
08-05-2025
- Business
- Yahoo
Manufacturer unveils game-changing project that could soon find its way to coffee drinkers worldwide: 'We continue to innovate'
Coffee just got a cleaner wake-up call thanks to a new paper-based pouch that could help shrink the industry's plastic problem. Amcor, one of the world's leading packaging companies, has launched the AmFiber Performance Paper stand-up pouch — a recyclable, paper-based solution designed for dry beverages like instant coffee, Clean the Sky reported. With 85% fiber content and certifications from CEPI and Aticelca, it's engineered to perform like traditional flexible packaging without the environmental baggage. According to Amcor, the pouch can help brands cut their carbon emissions by up to 73%, slash non-renewable energy use by 71%, and decrease water consumption by 41% compared to traditional flexible packaging. That's a significant step, especially considering that most conventional coffee packaging is made from plastic derived from dirty energy sources like oil and natural gas, materials that are tough to recycle and contribute to both carbon pollution and microplastic waste. "This newest addition to the AmFiber family offers coffee and dry beverage brands a more attractive packaging solution that has a natural, paper-based appeal and is recycle-ready," said Giorgio Dini, Amcor's coffee marketing manager. "Helping to advance more circular refill packaging, we are proud to announce the AmFiber Performance Paper stand-up pouch, as we continue to innovate in paper-based solutions." For consumers, it's a win on multiple fronts. The stand-up design keeps pantry shelves tidy and the contents fresh, while the recyclable materials support efforts to reduce single-use plastics at home. For the planet, it's a move away from dirty fuel-based packaging and toward a healthier climate future. Less plastic means less microplastics in our ecosystems and less air pollution that fuels extreme weather events and health risks. Amcor joins a growing list of companies investing in smarter, cleaner packaging options. Companies like Walmart, which is aiming to cut down its single-use plastic across its supply chain, and Nike, with its Move to Zero program, are part of a growing list of brands rethinking their environmental impact at scale. When you think about a product's packaging, which of these factors is more important to you? The way it looks The information it provides The waste it produces I don't think about packaging at all Click your choice to see results and speak your mind. As sustainability efforts face real-world challenges in cost and scale, innovations like this pouch offer a glimpse at how everyday products can evolve for the better without asking people to change their routines. Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
